Graham Capital Management, L.P.
Position in DNLI — Denali Therapeutics Inc.
CIK 1315421
ROWAYTON, CT
Position in DNLI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$403,006
+$103,829 QoQ
Shares Held
15,669
-13.5% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#162
of 290 holders
Holding Since
Jun 2023
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Graham Capital Management, L.P. holds $44,243,780 across 71 Biotechnology names. DNLI ranks #17 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TVTX |
Travere Therapeutics, Inc.
|
446,696 | $25,376,799 | |
| 2 | INCY |
Incyte Corp
|
15,632 | $1,772,043 | |
| 3 | IONS |
Ionis Pharmaceuticals Inc
|
16,717 | $1,325,490 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
22,114 | $862,667 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,256 | $679,123 | |
| 6 | ARVN |
Arvinas, Inc.
|
81,364 | $676,134 | |
| 7 | PCVX |
Vaxcyte, Inc.
|
11,107 | $645,649 | |
| 8 | MRVI |
Maravai Lifesciences Holdings, Inc.
|
92,277 | $575,808 |
All Filings in DNLI
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $403,006 | 15,669 | Shares | Sole | 2026-08-14 | |
| 2025-12-31 | $299,177 | 18,121 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $570,911 | 39,319 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $906,538 | 64,799 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $584,652 | 43,005 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $421,988 | 20,706 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $342,714 | 11,765 | Shares | Sole | 2024-11-14 | |
| 2023-06-30 | $932,840 | 31,611 | Shares | Sole | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||